Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Frequently asked questions
What sector does Ascendis Pharma AS (ASND) operate in?
Ascendis Pharma AS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Ascendis Pharma AS (ASND) current stock price?
As of the latest data, Ascendis Pharma AS stock price is $246.23, with a previous close of $255.46. Ascendis Pharma AS lost -$9.23 in the last trading session, representing a -3.61% loss.
What is Ascendis Pharma AS (ASND) current market capitalization?
Ascendis Pharma AS market cap is approximately 16.15 billion.
What is Ascendis Pharma AS (ASND) Earnings Per Share (EPS)?
The trailing EPS is $8.93, and the forward EPS is $9.29.
What is Ascendis Pharma AS (ASND) Price-to-Earnings (P/E) ratio?
Ascendis Pharma AS current P/E ratio is 27.57, with a forward P/E of 26.52.
What is Ascendis Pharma AS (ASND) EBITDA?
Ascendis Pharma AS EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 27.14 million.
Does Ascendis Pharma AS (ASND) pay dividends?
No. Ascendis Pharma AS does not pay a dividend.
How did Ascendis Pharma AS (ASND) perform in its most recent earnings report?
In the last report (June 30, 2026), Ascendis Pharma AS posted an EPS surprise of -37.21% and a revenue surprise of 6.53%.
What is Ascendis Pharma AS (ASND) beta (volatility) score?
Ascendis Pharma AS has a beta of 0.485, indicating lower volatility than the overall market.
